Erika Peverelli

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4514013/publications.pdf

Version: 2024-02-01

58 papers	1,635 citations	279798 23 h-index	302126 39 g-index
60 all docs	60 docs citations	60 times ranked	3774 citing authors

#	Article	IF	Citations
1	Pseudohypoparathyroidism andGNASEpigenetic Defects: Clinical Evaluation of Albright Hereditary Osteodystrophy and Molecular Analysis in 40 Patients. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 651-658.	3.6	144
2	Landscape of somatic mutations in sporadic GH-secreting pituitary adenomas. European Journal of Endocrinology, 2016, 174, 363-372.	3.7	100
3	Octreotide promotes apoptosis in human somatotroph tumor cells by activating somatostatin receptor type 2. Endocrine-Related Cancer, 2006, 13, 955-962.	3.1	92
4	Proliferation of Transformed Somatotroph Cells Related to Low or Absent Expression of Protein Kinase A Regulatory Subunit 1A Protein. Cancer Research, 2004, 64, 9193-9198.	0.9	88
5	Protective effect of TATâ€delivered Î±â€synuclein: relevance of the Câ€terminal domain and involvement of HSP70. FASEB Journal, 2004, 18, 1713-1715.	0.5	77
6	Autosomal Dominant Pseudohypoparathyroidism Type Ib: A Novel Inherited Deletion AblatingSTX16Causes Loss of Imprinting at the A/B DMR. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E724-E728.	3.6	68
7	Filamin-A Is Essential for Dopamine D2 Receptor Expression and Signaling in Tumorous Lactotrophs. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 967-977.	3.6	55
8	Dopamine receptor type 2 (<scp>DRD2</scp>) and somatostatin receptor type 2 (<scp>SSTR2</scp>) agonists are effective in inhibiting proliferation of progenitor/stemâ€like cells isolated from nonfunctioning pituitary tumors. International Journal of Cancer, 2017, 140, 1870-1880.	5.1	54
9	cAMP in the pituitary: an old messenger for multiple signals. Journal of Molecular Endocrinology, 2014, 52, R67-R77.	2.5	52
10	Somatostatin analogues increase AIP expression in somatotropinomas, irrespective of Gsp mutations. Endocrine-Related Cancer, 2013, 20, 753-766.	3.1	50
11	The dopamineâ€“somatostatin chimeric compound BIM-23A760 exerts antiproliferative and cytotoxic effects in human non-functioning pituitary tumors by activating ERK1/2 and p38 pathways. Cancer Letters, 2010, 288, 170-176.	7.2	49
12	Quantitative Analysis of Methylation Defects and Correlation With Clinical Characteristics in Patients With Pseudohypoparathyroidism Type I and GNAS Epigenetic Alterations. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E508-E517.	3.6	49
13	Evolution of an Aggressive Prolactinoma into a Growth Hormone Secreting Pituitary Tumor Coincident with GNAS Gene Mutation. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 13-17.	3.6	45
14	High expression of PKA regulatory subunit 1A protein is related to proliferation of human melanoma cells. Oncogene, 2008, 27, 1834-1843.	5.9	40
15	Filamin A (FLNA) Plays an Essential Role in Somatostatin Receptor 2 (SST2) Signaling and Stabilization After Agonist Stimulation in Human and Rat Somatotroph Tumor Cells. Endocrinology, 2014, 155, 2932-2941.	2.8	40
16	The Third Intracellular Loop of the Human Somatostatin Receptor 5 Is Crucial for Arrestin Binding and Receptor Internalization after Somatostatin Stimulation. Molecular Endocrinology, 2008, 22, 676-688.	3.7	39
17	Cyclic adenosine 3â€²-5â€²-monophosphate (cAMP) exerts proliferative and anti-proliferative effects in pituitary cells of different types by activating both cAMP-dependent protein kinase A (PKA) and exchange proteins directly activated by cAMP (Epac). Molecular and Cellular Endocrinology, 2014, 383, 193-202.	3.2	35
18	Dopamine receptor type 2 (DRD2) inhibits migration and invasion of human tumorous pituitary cells through ROCK-mediated cofilin inactivation. Cancer Letters, 2016, 381, 279-286.	7.2	33

#	Article	IF	Citations
19	Effect of Cyclic Adenosine 3â€²,5â€²-Monophosphate/Protein Kinase A Pathway on Markers of Cell Proliferation in Nonfunctioning Pituitary Adenomas. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 6721-6724.	3.6	32
20	Different expression of protein kinase A (PKA) regulatory subunits in cortisol-secreting adrenocortical tumors: Relationship with cell proliferation. Experimental Cell Research, 2008, 314, 123-130.	2.6	32
21	Characterization of Intracellular Signaling Mediated by Human Somatostatin Receptor 5: Role of the DRY Motif and the Third Intracellular Loop. Endocrinology, 2009, 150, 3169-3176.	2.8	29
22	Dopamine and Somatostatin Analogues Resistance of Pituitary Tumors: Focus on Cytoskeleton Involvement. Frontiers in Endocrinology, 2015, 6, 187.	3.5	28
23	Macroautophagy and the proteasome are differently involved in the degradation of alpha-synuclein wild type and mutated A30P in an in vitro inducible model (PC12/TetOn). Neuroscience, 2011, 195, 128-137.	2.3	26
24	Specific roles of Gi protein family members revealed by dissecting SST5 coupling in human pituitary cells. Journal of Cell Science, 2013, 126, 638-644.	2.0	24
25	Peripheral insulin-like factor 3 concentrations are reduced in men with type 2 diabetes mellitus: effect of glycemic control and visceral adiposity on Leydig cell function. European Journal of Endocrinology, 2009, 161, 853-859.	3.7	23
26	A novel pathway activated by somatostatin receptor type 2 (SST2): Inhibition of pituitary tumor cell migration and invasion through cytoskeleton protein recruitment. International Journal of Cancer, 2018, 142, 1842-1852.	5.1	22
27	Single-Molecule Microscopy Reveals Dynamic FLNA Interactions Governing SSTR2 Clustering and Internalization. Endocrinology, 2018, 159, 2953-2965.	2.8	22
28	Analysis of genetic variants of phosphodiesterase 11A in acromegalic patients. European Journal of Endocrinology, 2009, 161, 687-694.	3.7	21
29	cAMP/PKA-induced filamin A (FLNA) phosphorylation inhibits SST2 signal transduction in GH-secreting pituitary tumor cells. Cancer Letters, 2018, 435, 101-109.	7.2	21
30	Filamin-A is required to mediate SST2 effects in pancreatic neuroendocrine tumours. Endocrine-Related Cancer, 2016, 23, 181-190.	3.1	18
31	cAMP effects in neuroendocrine tumors: The role of Epac and PKA in cell proliferation and adhesion. Experimental Cell Research, 2015, 339, 241-251.	2.6	17
32	Filamin A in Somatostatin and Dopamine Receptor Regulation in Pituitary and the Role of cAMP/PKA Dependent Phosphorylation. Hormone and Metabolic Research, 2014, 46, 845-853.	1.5	16
33	Pituitary Tumors: Genetic and Molecular Factors Underlying Pathogenesis and Clinical Behavior. Neuroendocrinology, 2022, 112, 15-33.	2.5	16
34	PKA regulatory subunit R2B is required for murine and human adipocyte differentiation. Endocrine Connections, 2013, 2, 196-207.	1.9	14
35	Somatostatin analogs regulate tumor corticotrophs growth by reducing ERK1/2 activity. Molecular and Cellular Endocrinology, 2019, 483, 31-38.	3.2	14
36	Cytoskeleton actin-binding proteins in clinical behavior of pituitary tumors. Endocrine-Related Cancer, 2019, 26, R95-R108.	3.1	14

#	Article	IF	Citations
37	Cytoskeleton Protein Filamin A Is Required for Efficient Somatostatin Receptor Type 2 Internalization and Recycling through Rab5 and Rab4 Sorting Endosomes in Tumor Somatotroph Cells. Neuroendocrinology, 2020, 110, 642-652.	2.5	13
38	HESX1 expression in human normal pituitaries and pituitary adenomas. Molecular and Cellular Endocrinology, 2006, 247, 135-139.	3.2	12
39	Identification of human somatostatin receptor 2 domains involved in internalization and signaling in QGP-1 pancreatic neuroendocrine tumor cell line. Endocrine, 2017, 56, 146-157.	2.3	12
40	Genetic Profiling of a Cohort of Italian Patients with ACTH-Secreting Pituitary Tumors and Characterization of a Novel USP8 Gene Variant. Cancers, 2021, 13, 4022.	3.7	11
41	Stem Cells in Pituitary Tumors: Experimental Evidence Supporting Their Existence and Their Role in Tumor Clinical Behavior. Frontiers in Endocrinology, 2019, 10, 745.	3.5	9
42	Beta-Arrestin 2 Is Required for Dopamine Receptor Type 2 Inhibitory Effects on AKT Phosphorylation and Cell Proliferation in Pituitary Tumors. Neuroendocrinology, 2021, 111, 568-579.	2.5	9
43	Cofilin is a cAMP effector in mediating actin cytoskeleton reorganization and steroidogenesis in mouse and human adrenocortical tumor cells. Cancer Letters, 2017, 406, 54-63.	7.2	8
44	Drug resistance in pituitary tumours: from cell membrane to intracellular signalling. Nature Reviews Endocrinology, 2021, 17, 560-571.	9.6	8
45	Expression of protein kinase A regulatory subunits in benign and malignant human thyroid tissues: A systematic review. Experimental Cell Research, 2016, 346, 85-90.	2.6	7
46	Somatostatin Receptor Type 2 (SSTR2) Internalization and Intracellular Trafficking in Pituitary GH-Secreting Adenomas: Role of Scaffold Proteins and Implications for Pharmacological Resistance. Hormone and Metabolic Research, 2017, 49, 259-268.	1.5	7
47	The cytoskeleton actin binding protein filamin A impairs both IGF2 mitogenic effects and the efficacy of IGF1R inhibitors in adrenocortical cancer cells. Cancer Letters, 2021, 497, 77-88.	7.2	7
48	A Novel Mechanism Regulating Dopamine Receptor Type 2 Signal Transduction in Pituitary Tumoral Cells: The Role of cAMP/PKA-Induced Filamin A Phosphorylation. Frontiers in Endocrinology, 2020, 11, 611752.	3.5	7
49	Deciphering the specific role of GÎ±i/o isoforms: functional selective oxytocin ligands and somatostatin SST5 receptor mutants. Biochemical Society Transactions, 2013, 41, 166-171.	3.4	5
50	Cofilin is a mediator of RET-promoted medullary thyroid carcinoma cell migration, invasion and proliferation. Molecular and Cellular Endocrinology, 2019, 495, 110519.	3.2	5
51	Filamin A is required for somatostatin receptor type 5 expression and pasireotide-mediated signaling in pituitary corticotroph tumor cells. Molecular and Cellular Endocrinology, 2021, 524, 111159.	3.2	5
52	Octreotide and pasireotide effects on medullary thyroid carcinoma (MTC) cells growth, migration and invasion. Molecular and Cellular Endocrinology, 2021, 520, 111092.	3.2	4
53	P720R USP8 Mutation Is Associated with a Better Responsiveness to Pasireotide in ACTH-Secreting PitNETs. Cancers, 2022, 14, 2455.	3.7	3
54	DRD2 Agonist Cabergoline Abolished the Escape Mechanism Induced by mTOR Inhibitor Everolimus in Tumoral Pituitary Cells. Frontiers in Endocrinology, 2022, 13, .	3.5	3

#	Article	IF	Citations
55	Expression of the two alternatively spliced PRKAR1A RNAs in human endocrine glands. Molecular and Cellular Endocrinology, 2005, 238, 51-55.	3.2	1
56	Specific roles of Gi protein family members revealed by dissecting SST5 coupling in human pituitary cells. Journal of Cell Science, 2014, 127, 2377-2377.	2.0	0
57	GNAS, McCuneâ€“Albright syndrome, and GH-producing tumors. , 2021, , 197-223.		0
58	Somatostatin receptors regulation in corticotroph tumors: the role of cytoskeleton and USP8 mutations. Endocrine Oncology, 2022, , .	0.4	0